ResearcherGERCOR (France)No recent work listed
Annemilaï Tijeras‐Raballand
Matched on ORCID iD 0000-0001-5508-2566; OpenAlex author ID A5035411007. Sources: OpenAlex.
Their work
- Papers
- 9 (first author 3, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 30
2013: 2 papers · 2014: none · 2015: 3 papers · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper
Papers 9
- Pancreatic cancer orthotopic graft in a murine model. Co-author DOI 10.1590/acb382823↗
- Periostin- and podoplanin-positive cancer-associated fibroblast subtypes cooperate to shape the inflamed tumor microenvironment in aggressive pancreatic adenoc… Co-author DOI 10.1002/path.6011↗
- Microbiome and pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.clinre.2020.101589↗
- Inter- and intra-tumoural heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma. First author DOI 10.1002/path.5224↗
- State of the art and future directions of pancreatic ductal adenocarcinoma therapy. First author DOI 10.1016/j.pharmthera.2015.08.006↗
- High c-Met expression in stage I-II pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correlation with poor prognosis. Co-author DOI 10.1111/his.12691↗
- Targeting cancer cell metabolism in pancreatic adenocarcinoma. Co-author DOI 10.18632/oncotarget.4160↗
- Targeting the Ras-ERK pathway in pancreatic adenocarcinoma. Co-author DOI 10.1007/s10555-012-9396-2↗
- Stromal expression of SPARC in pancreatic adenocarcinoma. First author DOI 10.1007/s10555-013-9439-3↗
Closest collaborators
The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Cindy Neuzillet · 9 shared papers, 2013–2023 · strength 0.79
- Paper Pancreatic cancer orthotopic graft in a murine model. DOI 10.1590/acb382823↗
- Paper Microbiome and pancreatic ductal adenocarcinoma. DOI 10.1016/j.clinre.2020.101589↗
- Paper Periostin- and podoplanin-positive cancer-associated fibroblast subtypes cooperate to shape the inflamed tumor microenv… DOI 10.1002/path.6011↗
- Corinne Bousquet · 3 shared papers, 2019–2023 · strength 0.39
- Paper Pancreatic cancer orthotopic graft in a murine model. DOI 10.1590/acb382823↗
- Paper Periostin- and podoplanin-positive cancer-associated fibroblast subtypes cooperate to shape the inflamed tumor microenv… DOI 10.1002/path.6011↗
- Paper Inter- and intra-tumoural heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma. DOI 10.1002/path.5224↗
- Jerome F. Cros · 5 shared papers, 2013–2022 · strength 0.33
- Paper Periostin- and podoplanin-positive cancer-associated fibroblast subtypes cooperate to shape the inflamed tumor microenv… DOI 10.1002/path.6011↗
- Paper Inter- and intra-tumoural heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma. DOI 10.1002/path.5224↗
- Paper State of the art and future directions of pancreatic ductal adenocarcinoma therapy. DOI 10.1016/j.pharmthera.2015.08.006↗
- Rémy Nicolle · 2 shared papers, 2021–2022 · strength 0.28
- Marc Hilmi · 2 shared papers, 2021–2022 · strength 0.28
- Pascal R. Hammel · 5 shared papers, 2013–2019 · strength 0.26
- Paper Inter- and intra-tumoural heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma. DOI 10.1002/path.5224↗
- Paper State of the art and future directions of pancreatic ductal adenocarcinoma therapy. DOI 10.1016/j.pharmthera.2015.08.006↗
- Paper Targeting the Ras-ERK pathway in pancreatic adenocarcinoma. DOI 10.1007/s10555-012-9396-2↗
- Hemant Mahendrakumar Kocher · 2 shared papers, 2019–2022 · strength 0.20
- Victoire Cardot‐Ruffino · 1 shared paper, 2023 · strength 0.19
- Milena Muzzolini · 1 shared paper, 2023 · strength 0.19
- Renato Micelli Lupinacci · 1 shared paper, 2023 · strength 0.19
- Christine Jean · 1 shared paper, 2023 · strength 0.19
- Éric Raymond · 4 shared papers, 2013–2015 · strength 0.19
- Paper Targeting cancer cell metabolism in pancreatic adenocarcinoma. DOI 10.18632/oncotarget.4160↗
- Paper Targeting the Ras-ERK pathway in pancreatic adenocarcinoma. DOI 10.1007/s10555-012-9396-2↗
- Paper High c-Met expression in stage I-II pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correl… DOI 10.1111/his.12691↗
- Anne Couvelard Benveniste · 3 shared papers, 2013–2015 · strength 0.14
- Paper State of the art and future directions of pancreatic ductal adenocarcinoma therapy. DOI 10.1016/j.pharmthera.2015.08.006↗
- Paper Targeting the Ras-ERK pathway in pancreatic adenocarcinoma. DOI 10.1007/s10555-012-9396-2↗
- Paper High c-Met expression in stage I-II pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correl… DOI 10.1111/his.12691↗
- Vinciane Rebours · 1 shared paper, 2022 · strength 0.12
- Jérôme Raffenne · 1 shared paper, 2022 · strength 0.12
- Rémi Samain · 1 shared paper, 2022 · strength 0.12
- Valérie Paradis · 2 shared papers, 2015–2019 · strength 0.12
- Alain Sauvanet Sauvanet · 2 shared papers, 2015 · strength 0.09
- Anguraj Sadanandam · 1 shared paper, 2019 · strength 0.08
- Mert Erkan · 1 shared paper, 2019 · strength 0.08
- Francesca Romana Delvecchio · 1 shared paper, 2019 · strength 0.08
- Minoti Vivek Apte · 1 shared paper, 2019 · strength 0.08
- Jeremy S. Wilson · 1 shared paper, 2019 · strength 0.08
- Jorg H. Kleeff · 1 shared paper, 2019 · strength 0.08
- Romain Cohen · 1 shared paper, 2015 · strength 0.06
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.